

DECODING THE HUMAN IMMUNE SYSTEM TO DEVELOP NOVEL VACCINES FOR CANCER AND INFECTIOUS DISEASES WITH OUR AI-IMMUNOLOGY™ PLATFORM

N EVAX

a Monte I Marries Marri

Forward-looking statement

This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words "target," "believe," "expect," "hope," "aim," "intend," "may," "might," "anticipate," "contemplate," "continue," "estimate," "plan," "potential," "predict," "project," "will," "can have," "likely," "should," "would," "could," and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US. Securities and Exchange Commission (SEC), which are available at <u>www.sec.gov</u>. We do not assume any obligation to update any forward-looking statements except as required by law.

This presentation includes statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties or us. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. All of the market data used in this presentation involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. While we believe these industry publications and third-party research, surveys and studies are reliable, we have not independently verified such data. The industry in which we operate is subject to a high degree of uncertainty, change, and risk due to a variety of factors, which could cause results to differ materially from those expressed in the estimates made by the independent parties and by us.

A pioneer in fast and effective AI-powered development of new medicines



Multidisciplinary capability set and state of the art wetlab and animal facilities



Broad pipeline Preclinical and clinical programs across cancer and infectious diseases



Platform and pipeline

provides unique avenues for value creation



Multi-partner approach to value realization with several partnerships in place



Al-Immunology™ Clinically validated and leading AI platform

Deriving value from both our platform and pipeline

PLATFORM



Enables high value/low risk-partnerships on target discovery, design and development agreements PLUS fast and cost-effective replenishing of internal pipeline

- One stop-shop for pharmaceutical and biotech companies
- Full capability set

Al Immunology™

- Modality agnostic
- Scalable to multiple disease areas





Advancing select high value programs into preclinical and early clinical development, retaining value and leveraging multidisciplinary capability base

- Fast and effective preclinical validation
- Preclinical and clinical development capabilities
- Flexible in-house development to maximize value and monetization of assets

Summar

A transformative partnership with MSD

_
四
IЦ
ЪФ

Option and license agreement covering EVX-B2 and EVX-B3, offers fast and effective development to address serious unmet needs, no approved vaccines available today



Significant financial and strategic value to Evaxion, both short- and long-term



Upfront payment of \$3.2 million received in October 2024 and up to \$10 million in 2025, contingent upon MSD* exercising its option to license either one or both candidates




Milestone payments of up to potentially \$592 million per product plus royalties on sales, providing a very important source of income and funding for the years ahead



Massive validation of Al-Immunology[™] and pipeline from the world leader in vaccine development and commercialization

Further solidifies our collaboration with MSD, who is already our single largest shareholder with close to 20% equity stake



Targeting significant unmet needs and large markets

Major challenges

- 1 in 5 develop cancer in a lifetime¹. Lack of effective treatments for many cancer patients
- No approved vaccines against S. aureus, Gonorrhoea or Cytomegalovirus (CMV)
- Antibiotics resistance and healthcare burden continues to increase: 4.7 million deaths associated with resistance in 2021, expected to grow to 8.2 million in 2050⁶

10 million annual deaths from cancer¹

7.8 million

annual deaths from infectious diseases²



The power of AI-Immunology™ in vaccine target discovery, design and development

VALIDATED

AI Immunology™

clinical trials confirm predictive capabilities and link to outcomes

SCALABLE +100

different diseases can be addressed



Saving and improving lives with AI-Immunology™

FAST 24hrs to complete target discovery

TARGETED

80% fewer targets needs testing

AGNOSTIC



different modalities (protein, DNA, mRNA, peptides) validated

ACCURATE

79% vaccine target hit-rate

COST EFFECTIVE




on average cheaper target discovery versus reverse vaccinology

AI Immunology™


The unique architecture of AI-Immunology™

Strategy



AI Immunology[™]

Multidisciplinary capability set and state of the art facilities






AI-Immunology™ and our multidisciplinary capability set drive differentiation

- We believe our multidisciplinary capability set allows for:
 - Continuous iterative learning loops

AI Immunology[™]

- Ongoing expansion of data sets with proprietary data
- Rapid validation of AI predictions
- Full control of process from idea to validation
- Continued expansion of pipeline assets
- Significantly enhancing the value of our platform



Al Immunology™

Strategy

Pipeline: Demonstrating the performance and scalability of our AI-Immunology™ platform

INDICATION/			STAGE OF D	EVELOPMENT			
PATHOGEN		TARGET DISCOVERY	PRECLINICAL	PHASE 1	PHASE 2		
CANCER VACCINE	S						
Metastatic melanoma	Pembrolizumab supply agreement with MSD *	EVX-01 (Liposomal/peptide)				
Adjuvant melanoma		EVX-02 (DNA)**					
TBD		EVX-03 (Targeted DNA)					
Undisclosed		Multiple candidates					
INFECTIOUS DISEASE VACCINES							
S. aureus		EVX-BI (Proteins)					
N. gonorrhoeae	Option and license agreement with MSD *	EVX-B2 (Proteins)	S MSD				
N. gonorrhoeae	Collaboration with Afrigen for LMIC***	EVX-B2 (mRNA)	Afrigen Biologics & Vaccines Autorator Realth B.C. Company				
Bacterial pathogen	Option and license agreement with MSD *	EVX-B3					
Undisclosed		Multiple candidates					
Cytomegalovirus		EVX-V1					
Undisclosed				* Tradename of Merck & Co., Ind ** The data generated in the EV the development of the second *** Low- and middle-income co	(-02 program actively informs generation EVX-03 DNA vaccine		

Strategy

EVX-01: Peptide-based personalized cancer vaccine


HIGHLIGHTS

 Personalized vaccine for first-line treatment of advanced melanoma (skin cancer)

Al Immunology

- Vaccine targets (neoantigens) identified by Al-Immunology[™] based on individual tumor profile
- Combined with an anti-PDI antibody with the aim of improving clinical outcome

STAGE OF DEVELOPMENT



DISCOVERY	PRECLINICAL	PHASE 1	PI


Strategy

EVX-01: Peptide-based personalized cancer vaccine

 The combination of EVX-01 and anti-PD-1 therapy led to an ORR of 11/16 (69%)

Al Immunology

- In 15 out of the 16 patients, the target lesions were reduced
- 3/16 (19%) patients achieved complete remission of tumor target lesions




Al Immunology

Strategy

Significant protection against infectious diseases

EVX-B1


- Multi-component *Staphylococcus aureus* (SA) vaccine for prevention of Skin and Soft Tissue Infections (SSTI)
- Significant protection in lethal sepsis and skin infection mouse models. Immunized mice clear the infection from internal organs
- Large, non-rodent animals were protected against surgical site infections
- No prophylactic SA vaccine available today



Mouse sepsis model

EVX-B2

- Multi-component prophylactic vaccine against *N. gonorrhoeae* (Ng)
- Demonstrates exceptional efficacy against 50 clinically relevant Ng strains and significantly protects against Ng in a mouse infectious model
- Novel antigenic targets with unmet strain coverage
 and unique Mode-of-Action
- No prophylactic Gonorrhea vaccine available today



Vaginal colonization model

Al Immunology"

Strategic ambition and imperatives

Strategy


Maintain the leading AI platform



Al Immunology"

2025 milestones and value catalysts

Strategy



Al Immunology

Leadership team

Summary

Strong leadership with extensive experience across all relevant fields

Strategy











MSc Bioinformatics





Chief Scientific Officer

Birgitte Rønø

MSc Human Biology/ PhD





Chief Financial Officer

Thomas Schmidt

MSc Business Economics & Auditing



Amhu

Board of directors

- Marianne Søgaard Chair, former tech lawyer and equity partner
- **Roberto Prego** Former Teva (head of Latin America)
- Lars Holtug Certified Public Accountant
- **Lars Staal Wegner** VP Business Development, Hengrui Pharmaceuticals, MD

© Evaxion Biotech A/S. All rights reserved. 17

Strategy

Summary

Investment highlights

Al Immunology

- Truly Al-first company leveraging Al-Immunology™

 a pioneering clinically validated AI platform for vaccine discovery, design and development. Its modular architecture allows for unique scalability
- Pipeline of novel clinical and preclinical vaccine candidates for cancers and infectious diseases
- Proven ability to establish and manage a range of valuecreating partnerships
- Clear strategy with strong focus on monetizing value through business development
- Very solid business development pipeline
- MSD (via its MSD GHIF venture capital arm) largest shareholder with close to 20% equity stake

Capital structure

Symbol (Nasdaq - ADS)	EVAX
Stock price (as of March 31, 2025)	\$1.85
ADS outstanding if full conversion	6.3m
Market capitalization	\$11.7m
Warrants ¹ (WAEP \$10.48)	3.1m
Average trading volume	2.8m
Cash ²	\$6m
Debt ²	\$8m

1 Warrants convertible into ADS 2 As of Dec 31, 2024

